Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
15 mai 2020 02h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
Oyster Point Pharma Proposed Public Offering of Common Stock
12 mai 2020 16h20 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
Oyster Point Pharma Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
11 mai 2020 06h05 HE
|
Oyster Point Pharma, Inc.
ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal...
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
11 mai 2020 06h00 HE
|
Oyster Point Pharma, Inc.
Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash...
Oyster Point Pharma to Report First Quarter 2020 Financial Results on May 11, 2020
04 mai 2020 16h05 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business Update
30 mars 2020 07h30 HE
|
Oyster Point Pharma, Inc.
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma,...
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
27 févr. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm ET PRINCETON, N.J.,...
Oyster Point Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
24 févr. 2020 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference
24 févr. 2020 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease
12 janv. 2020 20h00 HE
|
Oyster Point Pharma, Inc.
OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control OC-01 nasal spray is a preservative-free, aqueous, nicotinic...